Quarterly ResultAug 6, 2026, 07:26 AM
Sionna Therapeutics Q2 Net Loss Widens to $29.9M; Cash $268.3M
AI Summary
Sionna Therapeutics reported a net loss of $56.7 million for the six months ended June 30, 2026, compared to $34.6 million for the same period in 2025, driven by increased research and development and general and administrative expenses. The company's cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026, which is expected to fund operations for over 12 months. Additionally, Sionna established an "at the market" equity offering program in March 2026 to sell up to $250.0 million in common stock, though no shares have been sold yet.
Key Highlights
- Net loss for the six months ended June 30, 2026, was $56.7 million, up from $34.6 million in 2025.
- Net loss per share for the six months was $(1.25) in 2026, compared to $(0.98) in 2025.
- Total operating expenses increased to $62.1 million for the six months, from $41.6 million in 2025.
- Cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026.
- Accumulated deficit grew to $313.0 million as of June 30, 2026.
- Established an "at the market" equity offering program for up to $250.0 million in March 2026.
- Unrecognized stock-based compensation expense was $79.7 million as of June 30, 2026.
Price Impact
More from SION